Board of Directors

Lui Franciosi, PhD

Lui Franciosi, PhD

Dr. Franciosi has more than 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior to Verona Pharma, Dr. Franciosi completed his post-doctoral research in COPD progression modeling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada – and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.

David Alexander

David Alexander

Mr. Alexander holds a Bachelor of Commerce in Finance from The University of British Columbia. His past achievements include; CFO of Arakis Energy Corporation, an international oil and gas development company, and managed the company’s growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company (Nasdaq: CRME).
Donald R. Carlow, MD

Donald R. Carlow, MD

Dr. Carlow was the past President and CEO (Jan 1994 – Oct 2000) of the British Columbia Cancer Agency (BCCA). Dr. Carlow’s efforts led to the development of new cancer centers, as well as laying the groundwork for the BC Cancer Research Center. Dr. Carlow was a member of the board of the Vancouver Island Health Authority, where he chaired the board’s health quality committee for four years. He proposed the establishment of the BC Council on Quality and Safety. Additionally, he acted as a judge for the 3M National Health Care Quality Awards for four years during the 90’s.

Yari Nieken, MBA

Yari Nieken, MBA

Mr. Nieken has a wide range of public company and capital market experience. He is Founder and President of Foremost Capital Inc. an Exempt Market Dealer. He is currently a director of Marapharm Ventures Inc. and has served on the boards of several public and private issuers including PUF Ventures (President & CEO), Lexagene Holdings Inc. (Director), Duport Capital Ltd (Director) and has raised substantial capital in his career. He holds an MBA from the Sydney Graduate School of Management and a BA from the University of British Columbia. He was formerly an investment advisor at Union Securities Corp. and continues to be a registrant in good standing in the provinces of British Columbia, Alberta, and Ontario.

Lorne Mark Rosenborough

Lorne Mark Rosenborough

Mr. Roseborough is currently the CEO of Sunvault Energy Inc. (OTCBB: SVLT) in Kelowna, B.C., which focuses on bringing cost effective energy generation and storage to the solar industry. He previously held the position as a Start-up Lead Executive for Dow Corning’s $1.2 billion Semiconductor plant in Clarksville, Tennessee. Mr. Roseborough was a director of EPOD Solar Inc. from October 2007 to January 2010. He also held management positions with EPOD Solar from 2003 and was promoted to vice-president and held that position from June 2008 until July 2009. From 1992 to 2003, Mr. Roseborough worked at Belkorp Industries, Inc. where he was vice-president of Manufacturing having direct responsibility for the operations of three pulp and paper mills and one small oil refinery. These operations had approximately 350 employees and $300 million in revenues. From November 1999 to 2003, he also held the position as President and CEO of Bluewater Fiber in Port Huron, Michigan (on behalf of owners Merrill Lynch and Cerberus Capital Partners) which was a large recycle pulp mill.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!